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Dengue virus (DENV) is a vector-borne, single-stranded positive-sense RNA virus with four distinct 
serotypes (DENV1-4). The four serotypes of DENV cause about 390 million human infections each year. 
The maturation of DENV during viral replication affects infectivity and antibody neutralization of the virus. 
The premembrane (prM) protein composition and the cleavage of the prM protein are determinants of 
DENV maturation. Across all four serotypes, the prM region is highly conserved. In particular, an N-linked 
glycosylation site that is located at the prM-N69 amino acid position is conserved across all but two 
strains of complete genomes provided by the ​Virus Pathogen Resource​ (ViPR) database. DENV prM 
glycosylation has not been extensively studied and there is no known function of the prM-N69 
glycosylation site. To investigate the impact of N69 glycosylation of the prM protein, we generated three 
DENV mutants with loss-of-N69 glycosylation mutations. Subsequently, we derived four more DENV 
constructs from the previous three mutants with loss-of-N69-glycosylation mutations and a new 
gain-of-glycosylation mutation at a site proximally near the prM-N69 region. Our results demonstrate no 
sign of viral production in any of the loss-of-N69-glycosylation constructs. In contrast, we show 
widespread signs of viral production in one construct, DENV4∆ADD2 (a glycosylation moving mutant). 
Our result suggests 1) the N69 glycosylation is critical for viral fitness and 2) glycan presence is sufficient 
for viral fitness. By understanding the importance of the DENV structures like pRM, we’ll be more 
informed for designing effective DENV vaccines for the future.  
Introduction 
Dengue virus (DENV) is a vector-borne, single-stranded positive-sense RNA virus with four distinct 
serotypes (DENV1-4). The four serotypes of DENV cause about 390 million human infections each year 
(Bhatt et al., 2013) and a third of the world's human population is at risk of infection (Stephenson, 2005). 
Most primary DENV infections result in asymptomatic infections. However, secondary infection can cause 
more severe illnesses, including dengue hemorrhagic fever (DHF) and Dengue Shock Syndrome (DSS) 
due to antibody-dependent enhancement (ADE) (Tripathi et al.,2018). There is currently no specific 
therapy available for the treatment of dengue diseases other than supportive care.  
The DENV genome (11kb) encodes a single polyprotein flanked by a 5’ and 3’ untranslated region (UTR). 
The polyprotein is post-translationally separated into three structural proteins (capsid [C], premembrane 
[prM], and envelope [E]) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and 
NS5) (Fig. 1A). The NS proteins participate in viral RNA replication, virion assembly, and evasion of host 
immune response (Idris et al., 2016). The RNA genome is encapsulated by the C protein which is 
 
surrounded by the host-derived lipid bilayer decorated with a layer of E glycoprotein (Kuhn et al., 2002) 
and M protein (the mature form of prM). The E protein plays an important role in host receptor 
attachment, cellular uptake of virion and membrane fusion. The prM protein acts as a chaperone to 
ensure proper E protein folding (Lorenz et al., 2002) and to prevent premature fusion of the virus (Li et al., 
2008; Yu et al., 2009). 
During DENV assembly, DENV goes through a maturation step in order to become infectious. The 
maturation process ensures stability for the viral particle during extracellular transmission and precise 
timing for membrane fusion during viral infection (Mukhopadhyay et al., 2005). DENV is initially 
assembled containing prM proteins, creating a pRM-E complex (Fig. 1B). The prM is eventually cleaved 
and as the virus leaves the cell, the cleaved portion dissociates, leaving fully mature viral particles (Fig. 
1C). The degree of maturation state and the relative amount of prM can alter the potency of antibodies 
that bind specific epitopes on E (Pierson et al., 2008). 
Glycosylation is the post-translational modification of biomolecules that involves attachment of complex 
oligosaccharide structures to a peptide backbone (Varki et al., 2015). N-linked glycosylation involves a 
glycan that is covalently attached to asparagine (N) in a consensus motif (peptide sequence) NxS or NxT 
(where x can be any amino acid other than proline) (Varki et al., 2015). Although some glycosylation 
confers no known function in the viral life cycle, several N-linked glycosylation sites in the DENV E 
glycoprotein can affect virus-mediated membrane fusion and neurovirulence. The glycosylation of the 
DENV prM/M glycoprotein has not been extensively studied but is thought to help prM act as a chaperone 
for E protein folding in the endoplasmic reticulum (ER) (Idris et al., 2016). Interestingly, sequence analysis 
of the DENV strains on the ​Virus Pathogen Resource​ database showed conservation of glycosylation of 
pRM at N69 is in all but two DENV isolates. Given the high conservation of the N69 glycosylation site, 
which is located at the surface-exposed portion of the prM protein (Fig 1B), we hypothesized a functional 
role of the N69 glycosylation in the viral life cycle. The two natural isolates that did not possess the N69 
glycosylation site were: DENV2 TSV01| VIPR_ALG4_14585843_439_936 (DENV2_TSVO1) and DENV4 
GD09/90| VIPR_ALG4_224551988_441_938 (DENV4_GD09/90). These two isolates provide a good 
model to understand the function of the N69 glycosylation site in the DENV maturation process. 
Furthermore, we hypothesize that the surface exposed N69 glycosylation site could modulate the 
antigenicity of the DENV virus and confer antibody evasion.  
 
 
Figure 1. Structure of DENV 
(A) A schematic representation of the DENV RNA genome, divided into structural and nonstructural genes. (B) 
Crystal structure of DENV E (grey) and prM (orange) monomer illustrated in ribbon form (PDB ID:4b03). The prM-N69 
glycosylation site is highlighted as spheres (yellow). (C) Immature (left) and mature DENV particle (right). The prM 
protein (orange) and E protein (grey) complex and protrude outward on immature DENV membrane (yellow), creating 
a jagged appearance. After prM is cleaved, the remaining M-E dimer creates the flat appearance for mature DENV 
particles. 
   
Figure 2. DENV prM sequence alignment 
Sequence alignment of DENV2 and DENV4 prM region. Only a portion of the sequence alignment and amino acid 
position from 50 to 90 is depicted. Original glycosylation site highlighted with a dark yellow box in DENV2_WT and 
DENV4_WT. Disruption in the N69 glycosylation site in DENV2_TSVO1 and DENV4_GD09/90, is highlighted in a 
light yellow box. A total of 1593 and 239 sequences from DENV2 and DENV4 were downloaded from the Virus 




Material & Methods  
Cells 
Mosquito (​Ae. albopictus)​ C6/36 cells were maintained in minimum essential medium (MEM) (Gibco, 
Grand Island, NY) media supplemented with 5% fetal bovine serum (FBS) (HyClone, Logan, UT),100 
U/mL penicillin and 100 mg/mL streptomycin (Gibco, Grand Island, NY), 0.1 mM nonessential amino 
acids (Gibco, Grand Island, NY), and 2 mM glutamine (Gibco, Grand Island, NY). All cells were incubated 
in the presence of 5% CO2 at 32 °C.  
Sequence Alignment 
Sequence alignment of the prM region was performed between 1,695 DENV2 and 272 DENV4 isolates 
(all of which had complete genomes) that were obtained from the ​Virus Pathogen Resource (ViPR) 
database​ ​(last accessed in March 2020)​. ​The resulting alignment, which was carried out by the MUSCLE 
program, was used to evaluate amino acid conservation among the multiple sequences. Two natural 
isolates, DENV2 TSV01| VIPR_ALG4_14585843_439_936 (DENV2_TSVO1) and DENV4 GD09/90| 
VIPR_ALG4_224551988_441_938 (DENV4_GD09/90), displayed irregularities in the widely conserved 
N69 glycosylation site in the prM protein. DENV2_TSVO1 and DENV4_GD09/90 were used as models for 
subsequent mutant constructions.  
Virus construction 
Recombinant viruses were constructed using a four-plasmid cloning strategy. The DENV genome was 
divided into four fragments (A−D fragment) and subcloned into four separate plasmids. A T7 promoter 
was introduced into the 5′ end of the A fragment, and unique type IIS restriction endonuclease cleavage 
sites are introduced into the 5′ and 3′ ends of each fragment to allow for systematic assembly into a 
full-length cDNA from which the full-length RNA transcripts can be derived. Plasmid DNA was grown in 
Escherichia coli​ cells, digested with the corresponding enzymes, gel purified, ligated together with T4 
DNA ligase. Ligation products were purified by chloroform extraction. The purified ligation product was 
used as a template for in-vitro transcription to generate infectious genome-length capped viral RNA 
transcripts using T7 RNA polymerase. RNA was electroporated into C6/36 cells. C6/36 cells infected with 
viral constructs were grown in Opti-MEM media (Gibco, Grand Island, NY) supplemented with 7% FBS. 
Cell culture supernatant containing virus was harvested 5 days post-electroporation as passage zero. 
During the subsequent passages following infection, the cells were grown in Opti-MEM media 
supplemented with 2% FBS.  
DENV2 and DENV4 mutant design 
The seven mutant constructs with the corresponding modifications in their prM region were generated in 
plasmid A in the DENV four-plasmid reverse genetic system by site directed mutagenesis. Three mutants 
only contained a disruption in the prM-N69 glycosylation motif and the other four mutants contained a 
disruption in the prM-N69 glycosylation motif and an additional glycosylation motif encoded at a separate 
location in the prM protein. The three mutants, one DENV2 and two DENV4 constructs, with 
loss-of-N69-glycosylation mutations were modeled after the two natural isolates: DENV2_TSVO1 and 
 
DENV4_GD09/90. The three-dimensional structure of all constructs was modeled by SWISS-MODEL 
(​https://swissmodel.expasy.org/​) using DENV1 immature particles as the template (PDB ID: 4b03). 
DENV2 and DENV4 wild type strains were used as backbones for the three loss-of-N69-glycosylation 
mutants. To disrupt the prM-N69 glycosylation site, amino acid substitutions (Table S1) that modeled the 
natural isolates were encoded into the wild type backbone to generate the three loss-of-N69-glycosylation 
mutants (DENV2∆GLY1, DENV4∆GLY1, and DENV4∆GLY2). Two of these mutants, DENV2∆GLY1 and 
DENV4∆GLY1, were subsequently used to derive the four other mutants (DENV2∆ADD1, DENV2∆ADD2, 
DENV4∆ADD1, DENV4∆ADD2). For each serotype, an additional glycosylation motif was encoded in one 
of two possible locations, prM-T27 or prM-R/V57, in the prM protein. These two positions were identified 
as being near the prM-N69 region in the tertiary prM structure (prM1-81) (PBD ID: 3C5X). A glycosylation 
motif beginning at prM-T27 or prM-R/V57 was encoded with amino acid substitutions (Table S1) that 
introduced new glycosylation sites in DENV2∆GLY1 and DENV4∆GLY1. Additionally, genomic markers, 
which are silent mutations that change the RNA sequence but maintain the same amino acid product, 
were inserted in several mutant constructs (Table S1). These markers help distinguish between 
constructs that have reverted back to its wildtype sequence or wildtype contamination. The new A 
fragments were digested and ligated with their respective wildtype plasmids B, C, and D to generate the 
seven mutant constructs.  
 
Site Directed Mutagenesis 
The A fragments of the viral constructs were mutated using site directed mutagenesis. This method used 
a pair of forward and reverse primers that were 25-56 base pairs long. The primers were designed to 
align with the desired sequence to be mutated. The forward and reverse primers were also designed to 
contain the desired mutations. Forward and reverse primers were centered on the desired base 
change(s) and the beginning of the forward primer is adjacent to the reverse primer. Extension of these 
primers around the entire plasmid created a copy of the template with the inserted mutation. The linear 
PCR products were then ligated back into the circular plasmid by T4 DNA ligase and transformed into 
E.coli.​ The sequence of the seven pairs of forward and reverse primers are shown in Table S2. 
Virus Immunostaining  
C6/36 cells were fixed in 10% PBS-buffered formalin every time the infected cells and supernatant were 
being passaged. Cells were blocked in 5% non-fat dried milk (permeabilization buffer) then incubated with 
anti-prM MAb 2H2 and anti-E MAbs 4G2 diluted 1:500 in permeabilization buffer. Cells were washed with 
PBS, then incubated with goat anti-mouse antibody conjugated with horseradish peroxidase (HRP) (KPL, 
Gaithersburg, MD) diluted 1:1000 in permeabilization buffer. Plates were washed and foci were 
developed using TrueBlue HRP substrate (KPL, Gaithersburg, MD). 
Results 
Deletion of prM-N69 glycosylation abolishes viral production in DENV2 and DENV4 
To evaluate the role of prM glycosylation in DENV life-cycle, we designed three constructs with mutations 
that disrupt the consensus N-linked glycosylation motif (N-X-S/T) in the prM protein. A mutant of DENV2 
(DENV2∆GLY1) and two mutants of DENV4 (DENV4∆GLY1 and DENV4∆GLY2) were generated with 
disruptions in their N69 glycosylation site (Fig. 3A). DENV2∆GLY1 and DENV4∆GLY1 resembled the 
 
naturally occurring N69 glycosylation disruption found in DENV2_TSVO1 and DENV4_GD09/90. On the 
other hand, DENV4∆GLY2 was designed to disrupt the N69 glycosylation site with the most minimal 
impact on the amino acid sequence. Each mutant was constructed and electroporated in C6/36 cells 
along with wild type DENV2 and DENV4 as positive control described in materials and methods. Each 
mutant was passaged five times in C6/36 cells and the cells were immunostained with 2H2 (anti-prM) and 
4G2 (anti-E) as an indication of the presence of viral replication after each harvest. In DENV2∆GLY1 and 
DENV4∆GLY1, immunostaining revealed sparse presence of viral protein production in the first passage 
but was subsequently lost after multiple passages. No virus was detected after the fifth passage. In 
contrast, wild type DENV2 and DENV4 showed robust virus production since the first passage and 
continuous throughout the experiment (three total passages) (Fig. 3B). In DENV4∆GLY2, immunostaining 
reveals virus production after the third passage. The viral titer was determined from the supernatant with 
2.1x10​6​ ffu/ml. Subsequent sequencing of the recovered virus revealed a single mutation, A71T which 
restored the N69 glycosylation to the original WT amino acid sequence. The resulting virus is a true 
revertant as the wild type codon is ACG and the revertant uses ACT to encode Threonine 71 (Fig. 3C).  
 
Figure 3. Viral presence of DENV2 variants with N69 glycosylation disruption  
(A) Wildtype prM-N69 glycosylation motif (left) and the expected amino acid substitutions in the mutant constructs 
(right) that disrupted the glycosylation motif. (B) Viral immuno-staining of C6/36 insect cells with DENV2_WT after 
passage one and three (left). Viral immuno-staining of C6/36 insect cells with DENV2∆GLY1 after passage one and 
five (right). Mouse monoclonal antibodies, 2H2 (anti-prM) and 4G2 (anti-E) were used to stain for signs of viral protein 
production. Peroxidase labeled goat anti-mouse IgG antibodies and KPL TrueBlue Peroxidase Substrate were used 
for signal detection. Blue staining indicates viral production. (C) Sequence chromatogram and amino acid sequences 
of prM-N69 glycosylation motif of wildtype (DENV4_WT) and DENV4∆GLY2 revertant.  
 
Insertion of glycosylation at a separate site in an N69 null prM variant  
Our unsuccessful attempts to rescue prM-N69 glycosylation null viruses argue the importance of the N69 
glycans or the primary sequence of the N69 region in DENV replication. In an attempt to dissect the 
underlying mechanism of the prM-N69 region and its function in viral replication, we evaluated the effect 
of moving the glycosylation site in close proximity to the prM-N69 region in both DENV2 and DENV4. 
Through structural analysis of DENV2 and DENV4 prM proteins, we identified two locations that were in 
close proximity to the original N69 site and have minimal impact on the primary sequence for inserting the 
glycosylation motif. The first location is at amino acid position 27 which is distanced from the original N69 
locations but is only 8.2A in tertiary structure. The second location is located at amino acid location 57 
which is close in both the primary sequence and secondary structure to the original N69 site (Fig. 4A, Fig. 
5A). Using N69 glycosylation deletion mutants, DENV2∆Gly1 and DENV4∆Gly1 as backbones, we 
generated DENV2∆ADD1 (T27N-D29T) and DENV4∆ADD1 (T27N-E29T) variants which introduce a new 
glycosylation motif at position 27. Using the same backbones, we also generate DENV2∆ADD2 
(R57N-N59T) and DENV4∆ADD2 (V57N) which moved the original N69 glycosylation site to position 57 
(Fig. 4B, Fig. 5B). While DENV2∆ADD1, DENV2∆ADD2, and DENV4∆ADD1 show sparse signs of viral 
production, DENV4∆ADD2 demonstrated signs of viral production similar to DENV4-WT after 
electroporation (Fig. 5C). After two passages, the sparse signs of virus production disappear from 
DENV2∆ADD1, DENV2∆ADD2, and DENV4∆ADD1. On the other hand, DENV4∆ADD2 demonstrates 
robust viral production similar to DENV4 WT (Fig. 5C). We subsequently isolated the genomic RNA of 
DENV4∆ADD2 and the sequence confirmed that DENV4∆ADD2 contains the desired V57N-N69D and 
the intended T59T marker mutations​. 
 
 
Figure 4. Viral immuno-staining of DENV2 variants with glycosylation reinsertion 
(A) The partial crystal prM tertiary structure (prM1-81) (PBD ID: ​3C5X​) in cartoon form of DENV2_WT, 
DENV2∆ADD1, and DENV2∆ADD1. The glycosylation site motif is highlighted as yellow, pink, and blue spheres in 
their respective models. Glycan stick residues (golden yellow) are adjacent to the glycosylation motif. (B) Specific 
amino acid substitutions that were inserted to create a new glycosylation motif at prM-T27 (left) or prM-R57 (right). 
(C) Viral signal of C6/36 insect cells with DENV4_WT after passage one and three. Viral signal of DENV2∆ADD1, 
and DENV2∆ADD1 after passage zero and three. 
 
 
Figure 5. Viral immuno-staining of DENV4 variants with glycosylation reinsertion 
(A) The partial crystal prM tertiary structure (prM1-81) (PBD ID: ​3C5X​) in cartoon form of DENV4_WT, 
DENV4∆ADD1, and DENV4∆ADD1. The glycosylation site motif is highlighted as yellow, pink, and blue spheres in 
their respective models. Glycan stick residues (golden yellow) are adjacent to the glycosylation motif. (B) Specific 
amino acid substitutions that are inserted to create a glycosylation motif at prM-T27 (left) or prM-V57 (right). (C) Viral 
signal of C6/36 insect cells with DENV4_WT, DENV4∆ADD1, and DENV4∆ADD1 after passage zero and two. 
 
Discussion 
So far, there has been limited exploration of the functions of N-linked glycosylation in DENV prM protein. 
However, the conservation of the prM-N69 glycosylation site across a majority of DENV2 and DENV4 prM 
proteins suggests the functionality of glycosylation. In this study, we explored the potential role of the 
DENV prM N69 glycosylation in viral maturation by modifying the N69 glycosylation site and glycan 
presence in the prM-N69 region.  
Through site-directed mutagenesis, we constructed three separate loss-of-glycosylation variants. We 
showed that such disruption in the prM protein ablated viral reproduction. Notably, DENV2∆GLY1 initially 
showed sparse signs of viral replication, however, these signs were eventually lost after several 
passages. This progression of viral signals leads us to hypothesize N69 glycosylation plays a role in viral 
assembly and propagation. When the N69 glycosylation site is disrupted, the RNA template may be able 
to successfully synthesize viruses in initial cells that were electroporated, hence the sparse appearance of 
viral staining (Env and prM). However, the resulting viral proteins may be unable to assemble into 
infectious viruses and infect the neighboring cells or propagate in later passages.  
While we were unable to show the replication of recombinant DENV with the loss of N69 glycosylation, we 
were able to recover a second site revertant with a functional glycosylation motif. In our study, 
DENV4∆GLY1 showed no presence of viral production while DENV4∆GLY2 produced a viral revertant. 
Although both mutations disrupted the glycosylation motif, the different outcomes might be a 
consequence of the type substitution that was directed in these two constructs. The DENV4∆GLY1 
mutated the asparagine (N) to aspartic acid (D) while DENV4∆GLY2 mutated threonine (T) to alanine (A). 
In the glycosylation motif (N-X-S/T), the glycan molecule specifically covalently bonds to asparagine (N) 
site. Given this, the N to D mutation is more disruptive than a T to A mutation. A change in the asparagine 
(N) site could potentially lead to more severe consequences and be more difficult to revert back from.  
Overall, a decrease in viral functionality was displayed in our loss-of-N69 glycosylation mutants. Our data 
strongly indicate that N69 glycosylation has a critical function in the viral life cycle, possibly during viral 
assembly. These results are consistent with previous research that suggests that the glycosylation of prM 
may allow it to act as a chaperone for the E protein and facilitate assembly of the E protein (Courageot et 
al., 2000). 
To gain a better understanding of the specific characteristics of the prM-N69 region, we investigated the 
effect of moving the glycosylation site to an alternate location that is proximally near the prM-N69 region. 
Our results showed that the addition of a glycosylation site at V57 in a DENV4 construct with a 
loss-of-N69 glycosylation mutation restored viral production. This suggests that glycan presence in the 
prM-N69 region is sufficient for DENV4 viral fitness.  
In order to gain a better understanding of the characteristics of DENV4∆ADD2, we will perform endpoint 
titers of viral stocks to investigate viral yield and perform viral growth curves to analyze growth properties. 
Since prM is a key determinant of DENV maturation, we will perform western blot analysis to determine 
the level maturation in DENV4∆ADD2. Lastly, the surface exposure of N69 glycosylation could also affect 
viral antigenicity and we will also carry out neutralization assay to test the antigenicity of our newly made 
DENV4∆ADD2 mutants.  
 
A comprehensive understanding of glycosylation pattern structure and functionality is an important 
component of therapeutic discovery and vaccine development.​ Some of the available drugs that disrupt 
protein glycosylation have led to incomplete maturation of DENV ​(Noble et al., 2010)​. In cases of severe 
dengue infection, where DENV replication can be enhanced by an antibody-dependent enhancement 
mechanism, these drugs are anticipated to be effective in limiting viral replication, thus reducing the viral 
load, which may lessen the severity of the disease ​(Idris et al., 2016)​.   
Conclusion 
In this study, we generated three constructs with loss-of-N69-glycosylation mutations and then derived 
four subsequent constructs from the previous mutants with an additional gain-of-glycosylation mutation 
that was proximally near the prM-N69 region. From two independent experiments, we were unable to 
generate a replicating recombinant DENV with the loss of N69 glycosylation. Instead, a second site 
revertant with a functional glycosylation motif was rescued after a prolonged period of time. Interestingly, 
the N69 glycosylation site null mutant can be rescued by providing an additional glycan at position 57. 
Our result suggests 1) the N69 glycosylation is critical for viral fitness and 2) The N69 glycan but not the 
primary amino acid sequence is the functional unit for viral fitness. Further research needs to explore the 
characteristics of the restored DENV4 mutant and investigate the role of N69 glycosylation in replication 
that may account for the production of small amounts of virus in the absence of N69 glycosylation. This 
information will support vaccine design and the discovery of antiviral therapeutics for DENV 
countermeasures. 
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Table S1.​ Names and Characteristics of Viral Constructs 




DENV​2​_TSVO1 Formal Name​: ​DENV2 TSV01| VIPR_ALG4_14585843_439_936  
Genomic irregularity in prM protein​: W67G, N69H 
 
Description: Natural DENV2 isolate with complete prM genome 
sequenced available via the Virus Pathogen Resource database 
DENV​4​_GD09/90 Formal Name​: ​DENV4 GD09/90| VIPR_ALG4_224551988_441_938  
Genomic irregularity in prM protein​: N69D, T73A  
Description: Natural DENV4 isolate with complete prM genome 
sequenced available via the Virus Pathogen Resource database:  
 DENV​2​_WT Formal Name​: DENV2-S16803 
Description: “Wildtype” / prototype backbone 
DENV​4​_WT Formal Name​: DENV4-Sri-Lanka 92 
Description: “Wildtype” / prototype backbone 
 DENV​2​∆GLY1 Mutations​: 
-Glycosylation disruption mutation:​ W67G , N69H 
-Marker mutation*:​ I64I , D65D 
Description:  The N69 glycosylation motif (N-X-S/T) is disrupted. 
In combination, ​W67G and N69H are meant to represent 
DENV2_TSVO1 irregularities.  
DENV​4​∆GLY1 Mutations​: 
-Glycosylation disruption mutation:​ N69D 
Description: The N69 glycosylation motif (N-X-S/T) is disrupted.  
 Mutation is meant to resemble DENV4_GD09/90 irregularities.  
DENV​4​∆GLY2 Mutations​: 
-Glycosylation disruption mutation:​ T71A 
Description: The N69 glycosylation motif (N-X-S/T) is disrupted.  
 
DENV​2​∆ADD1 Mutations​: 
-Glycosylation disruption mutation: ​W67G , N69H 
-​Glycosylation addition mutation:​ T27N, D29T  
-Marker mutation*:​ I64I , D65D 
Description:  
➢ The N69 glycosylation motif (N-X-S/T) is disrupted.  
In combination, ​W67G and N69H are meant to represent 
DENV2_TSVO1 irregularities.  
➢ Add ​N27​ glycosylation motif (N-X-S/T).  
DENV​2​∆ADD2 Mutations​: 
-Glycosylation disruption mutation: ​W67G , N69H 
-​Glycosylation addition mutation:​ R57N, N59T  
-Marker mutation*:​ I64I , D65D 
Description:  
➢ The N69 glycosylation motif (N-X-S/T) is disrupted.  
In combination, ​W67G and N69H are meant to represent 
DENV4_GD09/90 irregularities.  
➢ Add ​N57​ glycosylation motif (N-X-S/T).  
DENV​4​∆ADD1 Mutations​: 
-Glycosylation disruption mutation: ​N69D 




➢ The N69 glycosylation motif (N-X-S/T) is disrupted.  
Mutation is meant to resemble DENV4_GD09/90 irregularities.  
➢ Add ​N27​ glycosylation motif (N-X-S/T).  
DENV​4​∆ADD2  ​Mutations​: 
-Glycosylation disruption mutation: ​N69D 
-​Glycosylation addition mutation:​ V57N 
-Marker mutation*:​T59T 
Description:  
➢ The N69 glycosylation motif (N-X-S/T) is disrupted.  
Mutation is meant to resemble DENV4_GD09/90 irregularities.  
➢ Add ​N57​ glycosylation motif (N-X-S/T).  
 ​*​Marker mutations are mutations in base pair sequence that help indicate if the produced viral is from the mutated 
construct or wild type contamination if the amino acid change reverts. These are silent mutations. The sequence of 
nucleotide bases which constitutes RNA change, without a subsequent change in the amino acid. 
  
 
Table S2.​ Forward and Reverse primers to generate mutated A fragments 
 Virus Name  Primer 
 DENV​2​∆GLY1 Forward: GATTGTGGGTGCCACTCCACGTCCACATG 
Reverse: GATGTCTTCTGGCTCATTCTG 
DENV​4​∆GLY1 Forward: GACCTCACGTCTACCTGGGTC 
Reverse: GCACCAGCAATCAATGTCTTC 
DENV​4​∆GLY2 Forward: GCTTCTACCTGGGTCATGTATGGG 
Reverse: GAGGTTGCACCAGCAATCAATG 
 
DENV​2​∆ADD1 Forward: ​GAGACTGGTGTGAACATGTG 
Reverse: ​GTTTTTAAACAGAAGACTTTTCCCTTTC 
DENV​2​∆ADD2 Forward: ​CAGACTGAGCCAGAAGACATAG 
Reverse: ​GTTGAGAAGGGGACAGTTG 
DENV​4​∆ADD1 Forward: GGGGATCAACAAATGCACTC 
Reverse: GTTGTGTTCTTAAACAAGAGAGGTC 
DENV​4​∆ADD2 Forward: CTACTGAACAATACTGAACCTGAAGAC 
Reverse: GGGGCATTTATACGTGACAG 
 
 
 
